| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT03194893 A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive… |
Trial completed |
| 2026-06-12 | NCT03194893 A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive… |
Enrollment reduced: 200 -> 50 participants |
| 2026-06-12 | NCT03194893 A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive… |
date change Primary completion moved earlier: 2026-05-30 -> 2025-09-18 |
| 2026-06-12 | NCT03194893 A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive… |
date change Completion moved earlier: 2026-05-30 -> 2025-09-18 |
| 2026-05-23 | NCT04302025 A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages… |
Primary endpoint(s) modified |
| 2026-05-15 | NCT06765109 Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC |
Trial sites expanded: 149 -> 153 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06765109 | Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC | Non-small Cell Lung Cancer | Recruiting |
| NCT02838420 | A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib… | Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer | Active, Not Recruiting |
| NCT03768063 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd… | Cancer | Active, Not Recruiting |
| NCT03456076 | A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in… | Carcinoma, Non-Small-Cell Lung | Active, Not Recruiting |
| NCT05170204 | A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of… | Non-Small Cell Lung Cancer | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT03178552 | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments… | Non-Small Cell Lung Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT04116541 | A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular… | Malignant Solid Tumor | Recruiting |
| NCT04302025 | A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages… | Non-small Cell Lung Cancer | Recruiting |
| NCT04589845 | Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You… | Solid Tumors | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT05713006 | Alectinib Pharmacokinetic in Patients With NSCLC | Non-small Cell Lung Cancer Stage IIIB | Recruiting |
| NCT05987644 | Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With… | Lung Cancer | Recruiting |
| NCT04774718 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric… | ALK Fusion-positive Solid or CNS Tumors | Recruiting |
| NCT06624059 | A Study to See How Well and How Safely Different Treatments Work in a Group of… | Non-Small Cell Lung Cancer | Active, Not Recruiting |
| NCT03202940 | A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged… | Non-small Cell Lung Cancer | Active, Not Recruiting |
| NCT07560410 | Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib… | Bone Cancer | Not Yet Recruiting |
| Phase 1 | |||
| NCT07001384 | A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive… | Anaplastic Lymphoma Kinase | Recruiting |
| Not specified | |||
| NCT06862869 | Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated… | Carcinoma, Non-Small-Cell Lung | Recruiting |
| NCT04764188 | An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of… | NSCLC | Active, Not Recruiting |